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At a Glance Commentary: 
Scientific Knowledge on the Subject: 
Rhinitis and asthma are common clinical presentations of allergic airway disease and 
manifest Th2-mediated inflammation. Whereas airway remodeling is considered to be an 
important feature of asthma, little is known about the extent of tissue remodeling in nasal 
mucosa in allergic rhinitis. 
What This Study Adds to the Field 
Despite the presence of allergic inflammation in persistent rhinitis, there is no upper airway 
structural remodeling compared to healthy subjects. 
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Abstract 
Rationale: Increases in airway-smooth-muscle, extracellular-matrix, and vascularity are 
prominent features of airway-remodeling in asthma whereas the extent of such remodeling in 
persistent allergic rhinitics (PAR) patients is unknown. We aimed to test the hypothesis that 
upper-airway remodeling is a feature of PAR. 
 Methods: Total nasal symptom scores, nasal biopsies and Th1 and Th2 cytokines from nasal 
lavage were assessed in subjects with severe PAR (n=46) and healthy controls (n=19). 
Angio-lymphangiogenesis was examined using immunohistochemistry staining against CD31 
(Vascular endothelial cells), VEGF-A and D2-40 (Lymphatic endothelial cells). Collagen and 
extracellular matrix proteins such as HSP-47 (markers of collagen synthesis), MMP7-9 and 
TIMP1, and α-smooth–muscle-actin (myofibroblasts) were evaluated as markers of activation 
of upper airway remodeling using image analysis, together with reticular basement membrane 
(RBM) thickness, mucus gland area, collagen area and sub-mucosal effector inflammatory 
cells. 
Results: Total nasal symptoms scores, visual analogue scale and total quality of life were 
significantly higher in PAR compared to healthy controls (p<0.0001). Nasal lavage cytokine 
levels of IL-4 (p<0.01), IL-5, and IL-13 (p<0.001, respectively) were significantly higher in 
PAR compared to healthy controls. In addition there was an increase in sub-mucosal 
eosinophils (p=0.06).  No statistical difference in terms of angiogenesis, lymphangiogenesis, 
deposition of extracellular matrix, collagen markers, RBM thickness or glandular percentage 
area was observed between PAR and healthy controls.  
Conclusion: Our data suggest that tissue remodeling is not a feature of PAR and argues that 
in contrast to asthma, targeting remodeling in allergic rhinitis may not be appropriate as a 
therapeutic approach. 
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Introduction 
Tissue remodeling is by definition the reorganization or renovation of existing tissues. This is 
a process which is required to maintain normal tissue homeostasis and repair damaged tissue. 
Remodeling occurs in all inflammatory responses although the mechanism and severity vary 
depending on the disease (1,2).   
Allergic asthma is a chronic inflammatory disease involving ongoing inflammation and repair 
leading to structural airway remodeling. Although multiple mediators and growth factors 
such as Th2 cytokines, TGF-beta, MMP-9, ADAM-33 and VEGF have been considered to 
influence the airway remodeling process, currently there are no reliable clinical 
characteristics or surrogate markers that could identify lower airways remodeling (3). 
Structural changes that are implicated in lower airways remodeling such as epithelial 
shedding, thickening of basement membrane, angiogenesis, smooth muscle hypertrophy and 
deposition of collagens with subepithelial fibrosis are the features which are considered to 
contribute to airway obstruction and bronchial hyperreactivity (4-6).  
In allergic rhinitis, remodeling has received scarce interest and is not well understood. There 
are very few studies that investigate upper-airway structural remodeling in the nasal mucosa 
of allergic rhinitis and data is conflicting. It was reported that perennial allergic rhinitics had 
increased vascularity in nasal mucosa compared to healthy controls (7), while another study 
examined lower and upper airways of perennial allergic rhinitis patients with and without 
asthma and  compared them with healthy controls (8). In this study, it was demonstrated that 
even though similar inflammatory changes were present in both lower and upper airways of 
allergic rhinitis with and without asthma, no evidence of structural changes such as reticular 
basement thickness, epithelial desquamation and vascularity; was found in upper airways in 
allergic rhinitis as compared to healthy controls. 
Page 5 of 46  AJRCCM Articles in Press. Published on 17-September-2015 as 10.1164/rccm.201502-0339OC 
 Copyright © 2015 by the American Thoracic Society 
5 
 
We aimed to test the hypothesis that airway remodeling is a feature of allergic rhinitis and 
that it’s being driven by Th2 inflammatory responses in nasal mucosa. Nasal lavage and nasal 
mucosal biopsies were taken from severe persistent allergic rhinitis patients (PAR) and 
healthy controls. Local tissue inflammation, remodeling markers and tissue structure were 
evaluated. These studies have been previously been reported in part as an abstract (9).  
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Methods: 
Detailed methods and study design are described in the online supplement. 
Study Subjects 
Subjects aged 18-55 years with a clinical history of moderate-severe persistent allergic 
rhinitis according to ARIA (10) with a history of seasonal allergic rhinoconjuctivitis (May-
July) and/or perennial rhinitis to perennial allergens such as house dust mite with duration of 
at least two years or more requiring treatment were included. The study was approved by the 
ethics committee of The Royal Brompton and Harefield Hospitals NHS Trust and was 
performed with the subjects’ written informed consent (See supplement). 
Nasal Lavage procedure and measurement of nasal lavage cytokine levels 
Details of nasal lavage procedure and nasal lavage cytokine processing are in the online 
supplement. Briefly, for the electrochemiluminescence studies, the levels of IFN‐γ, IL‐4, IL‐
5, IL‐10, and IL‐13 in the nasal lavage samples were analyzed in duplicates using the Human 
Th1/Th2 10-plex Ultra-Sensitive kit from Meso Scale Discovery (MSD, Gaithersburg, MD). 
Assays were conducted according to standard manufacturer’s protocols. MSD plates were 
analyzed on the Sector Imager 6000 using MSD Discovery workbench software (v 3.0.17.3). 
Nasal Biopsy, immunohistochemistry staining and quantification 
Details of nasal biopsy processing are in the online supplement. Briefly, nasal biopsy 
specimens (2.5 mm) were taken from the under surface of the inferior turbinate using 
Gerritsma forceps. Immunohistochemistry was performed using the avidin biotin complex- 
alkaline phosphatase (ABC-AP) method as described previously (11) (see supplement).  
Biopsy sections were stained using monoclonal antibodies against eosinophils (MBP), mast 
cells (AAI) and basophils (2D7). Activation of upper airway remodeling was assessed by 
Page 7 of 46  AJRCCM Articles in Press. Published on 17-September-2015 as 10.1164/rccm.201502-0339OC 
 Copyright © 2015 by the American Thoracic Society 
7 
 
staining vascular (CD31) and lymphatic endothelial (D2-40) cells, and vascular endothelial 
growth factor-A (VEGF-A). Furthermore, extracellular matrix activation was evaluated by 
quantification of fibroblasts, alpha-SMA, MMP-7, MMP-9 and tissue inhibitor of 
metalloproteinase-1 (TIMP-1). Epithelial integrity and RBM were assessed using 
haematoxylin stained slides. Epithelial goblet cells and the glandular mucus area were 
evaluated using PAS staining. The collagen content was assessed by picrosirius red staining 
(12). Biopsies were coded and evaluated blindly by three investigators without the knowledge 
of clinical characteristics.  
Nasal mucosal inflammatory cells, were quantified using a BH-2 Olympus microscope. 
Epithelial integrity was scored on 0-4 scale, with 4 being an intact epithelium. Vascular and 
lymphatic staining was assessed using computer assisted image analysis (Image Pro-Plus 7.0 
system, Media Cybernetics, Inc). The whole specimen was captured at x200 magnification, 
using Nikon 80i light microscope coupled to colour camera (QImaging, Media Cybernetics, 
Inc) that transmits the image to a computer. Epithelial and sub-mucosal mucus glands, total 
sub-mucosal and vascular area were measured separately using computer image analysis. 
Reticular basement membrane thickness was measured as proposed by Sullivan et al (13). 
Epithelial and sub-mucosa cell counts were expressed as the number of positively stained 
nucleated cells per mm
2
.  
The total numbers of CD31
+
 and D2-40
+
cells in sub-mucosa were counted to a depth of 200 
µm below the epithelium. For each sample the percentage vascular area, the mean vessel size 
(mm
2
), and the vessel number (per mm
2
) within the total area of assessed sub-mucosa were 
evaluated. Percentage vascular area was calculated as [(total vascular area/sub-mucosal area) 
x 100]; number of blood vessels/mm
2
 (vessels density) as (total number of blood vessels/ 
total sub-mucosal area); and mean vessel size/mm
2
 (total vascular area/total number of blood 
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vessels). Furthermore, the relative lymphatic vessel density was studied by calculating the 
ratio of D2-40/CD31 positive vessels/mm
2
 (see supplement). 
Picrosirius stained collagens were quantified as previously described (12). Briefly, color 
images of two sections from each biopsy were acquired at x200 magnification (with a 
polarizing lens for picrosirius red–stained sections; Leica QWin version 3). Subsequently, 
images were converted to grayscale, and the area of positive staining that includes reticular 
basement membrane and whole of sub-mucosa was determined at a preset pixel intensity by 
using the Leica QWin software. The mean area of collagen and total sub-mucosal area was 
used to calculate the percentage area of collagen in each nasal biopsy. 
Statistics 
Values are presented as median [IQ 25-75 range], unless otherwise specified. Comparisons 
for quantitative variables were performed by non-parametrical analysis, Mann–Whitney U 
test for non-related samples. Differences between three groups were assessed using Kruskal-
Wallis test (nonnormal distribution) followed by Dunn's multiple comparisons test. Within-
group comparisons were performed using the Wilcoxon matched-pairs signed-rank test. 
Interobserver reproducibility was measured using Bland-Altman test, acceptable results were 
within 2 standard deviation. All tests were two-tailed. Significance was set at P<0.05. 
GraphPad Prism 5 Project software was used for analysis (see supplements statistics). 
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Results 
Subjects 
The demographic characteristics of the participants are summarised in Table 1 (see 
supplement). Among 46 persistent allergic rhinitics (PAR) subjects evaluated during the grass 
pollen season, 23 had a history of severe seasonal allergic rhinitis symptoms sensitised to 
Timothy grass and the other 23 had moderate-severe perennial symptoms and were sensitized 
to house dust mite (see supplement Table 2). Nineteen subjects were non-atopic healthy 
controls. Thirty one percent of PAR had current eczema or asthma (Table 1). 
Nasal symptoms, Visual analogue and Total Quality of Life scores  
Total nasal symptoms scores were statistically significantly higher in PAR groups compared 
to healthy controls (median [IQR]; 6 [4-9] vs 0 [0-1] respectively, p<0.0001). Total visual 
analogue score was significantly higher in PAR compared to controls (45 [23-67] vs 1 [0-7], 
p<0.0001) and the total quality of life scores were higher in PAR compared to controls (2 [1-
3.4] vs 0 [0-0.2], p<0.0001) (Table 1). Furthermore, on comparing subgroup analysis based 
on sensitization, both seasonal and perennial AR had significantly higher total nasal 
symptoms, visual analogue and total quality of life scores compared to healthy controls (see 
supplement Table 2). 
Nasal lavage cytokines in PAR and healthy controls  
Nasal lavage levels of IL-4, IL-5 and IL-13 were significantly higher in PAR patients 
compared to healthy controls (IL-4: 0.4 [0.2-0.6] vs 0.2 [0.1-0.3] p=0.01; IL5: 7 [5-12] vs 3.3 
[2.4-4.5] p<0.001; and IL-13: 7 [5-10] vs 5 [3-7] p<0.001, respectively) (Fig 1). Subgroup 
analysis showed IL-4, IL-5 and IL-13 were significantly higher in seasonal allergic rhinitis 
compared to healthy controls (p=0.02, p<0.001, and p<0.0001, respectively), while perennial 
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allergic rhinitis had higher nasal lavage IL-4 and IL-5 levels compared to healthy controls 
(p=0.04 and p<0.01, respectively). However, there was no difference in the levels of IL-10 
and IFN-γ between PAR and healthy controls or on subgroup analysis (data not shown). 
Nasal mucosal inflammatory cells 
The numbers of MBP
+ 
eosinophil were increased in the PAR group compared to controls, 
p=0.06, Fig 1 (for seasonal allergic rhinitis increases in eosinophils were significant, p=0.04). 
No changes in either mast cell or basophil numbers were observed in PAR group compared to 
healthy controls or when comparing subgroups and healthy controls (data not shown). 
Analysis of Epithelium, Reticular basement membrane and Glands  
The epithelial integrity and RBM thickness showed no difference between PAR and healthy 
controls (Table 2). Furthermore, total epithelial mucus and sub-mucosal glandular percentage 
area were similar in both groups (Fig 2 A & B, Table 2). On subgroup analysis according to 
sensitization, no differences were observed in terms of epithelial integrity, RBM thickness or 
glandular percentage area in the epithelium or sub-mucosa between seasonal and perennial 
allergic rhinitis and healthy controls. Additionally, no changes where observed when 
compared between in season and out of season (supplement table 3). 
Changes in Vascularity in Nasal sub-mucosa (blood and lymphatic vessels) 
There was no significant difference in the numbers of blood vascular endothelial cells 
(CD31
+
 cells), lymphatic endothelial cells (D2-40
+
 cells) or VEGF-A stained cells between 
PAR and healthy controls. Total numbers of blood and lymphatic vessels, percentage 
vascular area and mean vascular size in the nasal sub-mucosa showed no difference between 
the two groups (Fig 2 C-F, Table 2). There was no significant difference when analysing the 
numbers of VEGF-A positive blood vessels, VEGF-A
+ 
vascular area or mean VEGF-A
+ 
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vascular size between the groups. The relative lymphatic vessel density was analysed by 
determining the ratio of D2-40 / CD31 positive vessels/mm
2
, which showed no statistical 
difference between the two groups (Table 2).  
Furthermore, on subgroup analysis no differences were observed when comparing seasonal, 
perennial and healthy controls in terms of blood and lymphatic endothelial positive cells, total 
vascular numbers, vascular area or mean vascular size for both blood and lymphatic vessels. 
There was also no difference in lymphatic vessel density on subgroup analysis (supplement 
table 3).     
Sub-mucosal Extracellular and Collagen Markers  
Expression of sub-mucosal MMP-7, MMP-9 and TIMP-1 were not significantly different 
between PAR and healthy controls (Fig 3 A-F, Table 2). The ratio of MMP9/TIMP-1 was not 
significantly different between the two groups. No difference was observed when comparing 
between seasonal, perennial and healthy controls for all analysed extracellular matrix protein 
markers. On comparing seasonal allergic rhinitis subjects during and out of season, a 
significant increase in TIMP-1 was observed in out of season biopsies compared to during 
pollen season, while no changes were observed for MMP-7 and MMP-9 when seasonal 
allergic subjects were compared in season and out of season (supplement table 3). 
The expression of nasal mucosal fibroblasts (Fig 4 A,B) and α-SMA cell numbers (Fig 4 
C,D) were not significantly different between PAR and healthy controls (Table 2). No 
difference was observed when comparing seasonal, perennial and healthy controls for all 
analysed fibrotic markers. Furthermore, no changes were observed when seasonal allergic 
subjects were compared in season and out of season (supplement table 3). When analysing 
collagen content in nasal mucosa using polarised light, both larger collagen fibers in bright 
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orange and thinner fibers in green were present in nasal sub-mucosa of all subjects. There 
was no significant difference in collagen area between PAR and healthy controls (Fig 4 E,F). 
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Discussion 
The current study demonstrated that persistent allergic rhinitis is characterised by increased 
levels of local nasal secretion of IL-4, IL-5 and IL-13 Th2 cytokines and local tissue 
eosinophilia but no structural changes nor evidence of remodelling. Epithelial integrity, 
reticular basement membrane thickness and the nasal mucosal glandular area were not 
different between PAR and controls. Furthermore, there was no difference in blood and 
lymphatic vascularity, fibrosis or collagen deposition nor degradation of extracellular matrix 
markers observed between the groups. In contrast to asthma, remodeling is not a feature of 
allergic rhinitis. This questions the current dogma on the relation between the upper and 
lower airways and argues that in contrast to asthma, targeting remodeling in allergic rhinitis 
may not be appropriate as a therapeutic approach. 
To our knowledge, this is the first study to compile and evaluate the expression of 
remodeling-related proteins in the upper-airways of allergic rhinitis patients looking both in 
nasal lavage and nasal biopsies in one setting. The current study included adequate sample 
size and used strict inclusion criteria to ensure that a well characterised group of subjects with 
moderate to severe persistent allergic rhinitis according to Aria guidelines could be observed 
alongside a group of normal healthy controls.  
Lower airway remodeling is considered to occur due to chronic inflammation and eosinophils 
are thought to be the cells that orchestrate the production of cytokines, growth factors and 
mediators leading to proliferation and differentiation of fibrotic cells that leads to collagen 
deposition and tissue fibrosis (14-16). The current study found an increase in Th2 cytokines 
within nasal secretions and sub-mucosal eosinophils in persistent allergic rhinitis confirming 
a local intense inflammation. This corresponds to our previous finding that both  seasonal 
(17, 18) and perennial allergic rhinitis (19) are associated with an increase in tissue 
eosinophils and with an increase in nasal mucosal cells expressing mRNA for the Th2-type 
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cytokines compared to healthy controls. This is in line with previous studies that compared 
nasal and bronchial tissue with eosinophilia in persistent allergic rhinitis and found that the 
upper airway has similar intense inflammation compared to lower airways in the same 
individuals (8, 20) but that the chronic inflammation didn’t alter upper airway mucosal 
structural changes (21). Hence, the present study confirms that although there is allergic 
inflammation in the upper airways of PAR subjects, remodeling changes such as epithelial 
integrity loss, RBM thickness, nasal tissue glandular hypertrophy, vascularity and collagen or 
extracellular matrix deposition are indistinguishable between PAR and healthy controls. 
It has been well documented that angiogenesis is a characteristic feature of remodeling in 
asthma (22,23). Although increased vascular permeability is observed in allergic rhinitis (24), 
evidence showing angiogenesis or gross structural vascular changes are lacking.  Our data 
confirms previously published reports (8,25) showing no difference in the total number of 
CD31
+
 cells, blood vessels, vascular density nor mean vascular size in the nasal mucosa of 
allergic rhinitics compared to controls. Furthermore, on evaluating angiogenic growth factors, 
there were no changes in the upregulation of VEGF-A expressing cells or their stained 
vessels in the nasal mucosa observed between the groups. In addition, using D2-40 staining 
which is considered a sensitive and specific marker for lymphatic endothelium (26), no 
difference in the numbers, density or mean volume of lymphatic vessels was observed 
between the two groups. Taken all together, our study does not indicate that angiogenesis or 
lymphangiogenesis is the feature of upper airway remodeling in allergic rhinitics. 
Matrix metalloproteinases are major proteolytic enzymes that are involved in extracellular 
matrix turnover. We examined MMP-7 and MMP-9 because they are believed to cleave 
major collagen components of extracellular matrix and basement membrane. The 
extracellular activity of MMPs is regulated by TIMPs, which are produced by the same cell 
types that produce MMPs, and TIMP-1 has been implicated as a natural inhibitor of both 
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MMP-7 and 9 (27-28). It has been shown that MMP7 and 9 is upregulated in chronic rhino-
sinusitis with or without polyps (29) and the ratio of MMP-9/TIMP-1 is increased in 
asthmatics (30-31). Recently it has been demonstrated that only MMP-9 but not MMP-2 or 
TIMP-1 mRNA expression is increased in nasal mucosa of severe perennial allergic rhinitis 
compared to mild rhinitics and healthy controls (32). We had anticipated that patients with 
PAR would have increased expression of MMPs and an imbalance of TIMP. However, in the 
present study we did not find any difference in MMP-7, MMP-9 or TIMP-1 between PAR 
and healthy controls. This is in line with previous reports that found no significant difference 
in both protein and mRNA transcript levels of MMP-9 or TIMP-1 in the nasal mucosa of 
perennial allergic rhinitis compared to healthy controls (33).  
Subepithelial fibrosis is an important feature of airway remodeling in asthma which is 
attributable to an increased deposition of extracellular matrix (34). Fibroblasts and myo-
fibroblasts are the main sources of extracellular matrix proteins in the airways subepithelial 
fibrosis with TGF-beta being the main player that promotes differentiation of fibroblasts to 
myo-fibroblasts phenotypes (those expressing α -SMA) triggering their proliferation (31, 35, 
36). We found a similar degree of expression of HSP-47
+
 fibroblasts cells and α -SMA
+
 cells 
in both PAR and healthy controls. In addition, total collagen area was the same in both PAR 
and healthy control nasal mucosa. Thickening of RBM due to deposition of collagens is a 
common feature of asthmatic airway remodeling, however the present study demonstrated no 
difference in changes in nasal mucosal subepithelial basement membrane between healthy 
and PAR patients confirming that there is no upper-airway structural difference between 
allergic rhinitics compared to healthy individuals. Recently, it has been shown in an in-vitro 
study that TGF-beta enhances expression of both α-SMA and collagen production in lung 
fibroblasts but not in nasal polyp fibroblasts highlighting the heterogeneous response of 
fibroblasts in the airway to TGF-beta between the upper and lower airway tissues (37).  
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Recent studies have suggested that structural airway changes in asthmatics can occur after 
resolution of or in the absence of inflammation due to the induction of epithelial stress by 
airway hyperreactivity which initiates bronchial airway remodeling (38,39). Hence 
supporting the emerging concept that the epithelial-mesenchymal trophic unite (EMTU), the 
embryologic unit driving airway development, is being reactivated in airway remodeling 
through genetic and environmental interactions. This concept suggests that activated airway 
epithelial cells promote mesenchymal signalling inducing myofibroblast transformation 
which initiates wound healing in asthmatics (40).  
A recent study (41) examined sinonasal epithelial markers and lineage differentiation in 
participants with chronic rhinosinusitis (CRS) with and without polyps, allergic rhinitis and 
healthy controls. In CRS (with and without polyps) but not in allergic rhinitis, a significant 
decrease was observed in the expression of proteins associated with adherens and tight 
junctions, and an increase in intracellular vimentin filaments  that correlated with 
subepithelial fibrosis and disease severity. These findings imply that alterations in the EMTU 
occur in CRS but not in allergic rhinitis or healthy controls. Interestingly, CRS with and 
without polyps differ in immunopathological mechanisms, hence indicating that EMTU and 
remodeling might occur independently of inflammatory or immune changes. This study adds 
weight to our findings that Th2 inflammation as occurs in allergic rhinitis might not 
contribute to tissue remodeling or activation of the EMTU.    
 Furthermore, a recent report that analysed gene expression profiles of upper and lower 
airway epithelial cells in the same individuals comparing those with rhinitis and asthma, 
rhinitis without asthma and controls, revealed that the majority of transcriptional factor genes 
(FOXP2,A1,A2, NKX2-1 and GATA6) that are involved in lung development were 
differently expressed between healthy upper and lower airways (42) which supports the 
hypothesis that the different embryologic origins of the nose and bronchi genes might be 
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responsible for the absence of remodeling in the nose in rhinitis compared to the bronchi in 
asthma (1).  
Our result are also in line with recent data that showed treating chronic sinonasal disease does 
not improve asthma control (43,44). Hence, our results might support the notion that either 
the upper airways respond differently to allergic inflammation than the lower airways or that 
there are factors other than eosinophils or Th2 cytokines which drive the response in the 
lower airways.   
In conclusion, our data suggests that despite the presence of Th2 allergic inflammation in 
persistent allergic rhinitis, there is no upper airway structural remodeling compared to healthy 
subjects. The impact of our findings is that in contrast to asthma, structural changes and 
remodeling are not features of allergic rhinitis. This questions the current dogma on the 
relation between the upper and lower airways and argues that in contrast to asthma, targeting 
remodeling in allergic rhinitis may not be appropriate as a therapeutic target. 
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Legends: 
Figure 1: Th2 cytokine (IL-4, IL-5, IL-13) levels from nasal lavage and sub-mucosal 
eosinophils comparing persistent allergic rhinitis and healthy controls. PAR: Persistent 
allergic rhinitis. Horizontal bars represent median values, p value: <0.05: statistical 
significance, Mann-Whitney test. 
Figure 2: Blood and lymphatic vessels stained using immunohistochemistry, and PAS 
stained glandular structures. A-B): The percentage total area of nasal sub-mucosal glands 
comparing persistent AR and controls. C-D): Percentage total area of blood vessels stained 
using CD31
+
. E-F): Percentage total lymphatic vascular area in nasal sub-mucosa stained 
using D2-40 antibody. PAR: Persistent allergic rhinitis. Horizontal bars represent medians. 
Figure 3: Immunoreactivity and localization of matrix metalloproteinases-7 and 9 (MMP-
7,9), and tissue inhibitor metalloproteinases-1 (TIMP-1) in the nasal sub-mucosa of persistent 
allergic rhinitis and healthy controls. No significant different in the expression of MMP-7 (A-
B), MMP-9 (C-D) and TIMP-1 (E-F) in persistent allergic rhinitis compared to healthy 
controls nasal sub-mucosa. Horizontal bars represent medians. 
Figure 4: Markers of collagen deposition comparing persistent allergic rhinitis and healthy 
controls are shown in A to F.  The collagen chaperone heat shock protein (HSP)-47
+
 
fibroblasts and α-smooth muscle actin (α-SMA-expressing myo-fibroblasts) (as positive 
stained cells per mm
2
) are shown in A through D, respectively. Fibroblasts were fusiform 
with elongated nuclei. Picrosirius red stained sections of nasal mucosa from persistent 
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allergic rhinitis and healthy controls assessed for total collagen deposition using polarised 
light microscopy are shown in E-F. Horizontal bars represent medians. 
 
Table 1: Demographic features of participants 
 
Persistent allergic rhinitis 
n=46 
Healthy control 
n=19 
P value 
Age yrs 30 (23-40) 30 (26-45) 0.47 
Gender F/M 24/22 11/8 0.68 
TNSS 6 (4-9) 0 (0-1) <0.0001 
TVAS 45 (23-67) 1 (0-7) <0.0001 
Total RQoL 2 (1-3.4) 0 (0-0.2) <0.0001 
Eczema % 21 (n:10) - (n:0) <0.0001 
Asthma % 30 (n:13) - (n:0) <0.0001 
sIgE grass IU/mL 11 (3.7-34.4) 0 (0) <0.0001 
sIgE HDM IU/mL 15.7 (3-36) 0 (0) <0.0001 
Total IgE IU/mL 157 (58-404)  15 (4-49) <0.0001 
Definition of abbreviations: TNSS= Total nasal symptoms score, TVAS= Total visual 
analogue score, RQoL= Rhinitis quality of life, sIgE= Specific IgE, n= Number of subjects.  
Median (IQR:25-75 %) 
 P: Mann-Whitney test comparing persistent allergic rhinitis and control 
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Table 2: Summary of airway remodeling markers in upper airways in severe persistent 
allergic rhinitis and healthy controls 
Natural exposure (severe persistent allergic rhinitis-PAR) 
  
Healthy 
controls 
 PAR 
P values 
Epithelial Mucus % Area 
 
10 (3-22)  17 (4-38) 0.43 
RBM Thickness 
 
9 (7-10)  8 (6.5-10) 0.50 
Sub-mucosal Glandular 
% Area/ mm
2
  
34(21-43)  32(17-45) 0.98 
CD31
+
 Cells /mm
2
 
 
333 (180-566)  367 (213-472) 0.68 
CD31
+
 % Vascular Area/ mm
2
 
 
1.7 (1.1-3.9)  1.5 (0.4-3.4) 0.38 
Number of Blood vessels/mm
2
 
 
41.3 (18-58)  37.7 (29-51) 
0.65 
Mean size blood vessels/µm
2
 
 
532 (270-1010)  372 (131-931) 
0.12 
D2-40
+
 Cells/ mm
2
 
 
0 (0-51)  0 (0-38) 
0.76 
D2-40
+
 % Vascular Area/ mm
2
 
 
0 (0-0.2)  0 (0-0.5) 
0.69 
Number of Lymphatic vessels/mm
2
 
 
0 (0-6)  0 (0-6) 
0.74 
Mean size Lymphatic vessels/µm
2
 
 
0 (0-494)  0 (0-601) 
0.70 
D2-40
+
/CD31
+
 vessels/mm
2
 ratio  0 (0-0.19)  0 (0-0.1) 
0.84 
D2-40
+
/CD31
+
 % vascular area/mm
2
 
ratio 
 0 (0-0.1)  0 (0-0.15) 
0.87 
VEGF-A
+
 cells/ mm
2
 
  
80 (0-129)  52.1 (0-121) 
0.59 
VEGF
+
 % vascular Area/ mm
2
 
 
0.2 (0-0.7)  0.2 (0-1.2) 
0.99 
Number of VEGF
+
  vessels/mm
2
 
 
10 (0-21)  10 (0-19) 
0.68 
Mean size VEGF
+
 vessels/µm
2
 
 
45 (0-177)  40 (0-277) 
0.90 
MMP-7
+
 cells/ mm
2
 
 
1 (0-60)  0 (0-8) 
0.20 
MMP-9
+
 cells/ mm
2
 
 
6.7 (0-27.7)  7 (0-21) 
0.95 
TIMP-1
+
 cells/ mm
2
 
 
0 (0-3)  0 (0-4) 
0.91 
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HSP-47
+
 Fibroblast/mm
2
 
 
0 (0-15)  0 (0) 
0.06 
α-SMA/ mm
2
 
 
130 (62-217)  105 (56-185) 
0.45 
Definition of abbreviations: α-SMA= Alpha smooth muscle actin, TIMP= Tissue inhibitor metaloproteinase, 
MMP= Matrix metalloproteinase, HSP= Heat shock protein, VEGF= Vascular endothelial growth factor, 
CD31= Vascular endothelial cells, D2-40= Lymphatic endothelial cells, RBM= Reticular basement membrane, 
PAR= Persistence allergic rhinitis. Median (25%-75%). 
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Methods:  
Study Subjects 
Subjects aged 18-55 years with clinical history of moderate-severe persistent allergic rhinitis 
according to ARIA (E1), with a history of seasonal allergic rhinoconjuctivitis (May-July) 
and/or perennial rhinitis to perennial allergens such as house dust mite with duration of at 
least two years or more requiring treatment were included.  All atopic subjects had a positive 
skin response (wheal diameter ≥ 3 mm) and a positive specific IgE against aeroallergens (≥ 
0.73 kU/ml). Non- atopic healthy controls were subjects without any nasal symptoms, 
negative skin test and no specific IgE to aeroallergens. Other inclusion criteria were no 
clinically relevant findings on physical examination and willingness to comply with this 
study. Patients were excluded if they smoked, used systemic steroid treatment for 6 weeks or 
topical steroid treatment for 2 weeks prior to the start of the study, had a history of 
anaphylaxis, family history of bleeding, currently used non-steroidal anti-inflammatory drugs 
or immunosuppressive medication, had other nasal or systemic chronic diseases, severe 
asthma or specific immunotherapy within the last 5 years. All subjects were recruited via 
advertising in print and on-line from the general public, Imperial College and Royal 
Brompton Hospital staff .The study was approved by the ethics committee of The Royal 
Brompton and Harefield Hospitals NHS Trust and was performed with the subjects’ written 
informed consent. 
Study design  
Each subject was required to make 2 separate visits. After the screening visit eligible 
participants were scheduled for a second visit during the pollen season to provide symptom 
scores, rhinitis quality of life visual analogue score and nasal lavages to determine 
inflammatory response remodeling markers immediately prior to the nasal biopsies as shown 
in E-Fig 1. 
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Skin prick test: 
Skin prick testing was performed with a sterile stainless steel lancet (ALK Abello, Denmark) 
and standardized reagents [Timothy grass Phleum Pratense extract, mixed grass pollen, birch 
pollen, mixed tree, cat hair, dog hair, house dust mite (Dermatophagoides pteronyssinus), 
mixed weeds, Aspergillus fumigatus, Cladosporium herbarum, Alternaria alternata, 
Soluprick; ALK Abello]; a wheal of >3 mm compared with the diluent (negative control) was 
considered positive. 
 
Symptoms scores, Visual analogue score and quality of life  
Symptoms scores were evaluated using a four-point scoring system: 0 (no symptoms) to 3 
(severe symptoms) for each rhinitis symptom (sneezing, nasal discharge, itching and nasal 
obstruction). Subjects were asked to score their symptoms when they were most severe 
during the last week. The total score of all four rhinitis symptoms was termed the total nasal 
symptom score (TNSS) (maximum 12 points). Total nasal symptom scores were recorded 
before collection of nasal lavage and biopsy procedures. Quality of life in relation to 
symptoms was assessed using mini Rhinitis Quality of Life Questionnaires (mRQLQs). 
Participants were asked to mark a visual analogue scale (scale 0-100 mm) documenting the 
overall severity of their allergic rhinitis symptoms during the past week. 
 
Nasal Lavage procedure and measurement of nasal lavage cytokine levels 
Subjects were seated in a forward-flexed neck position to prevent fluid from reaching the 
nasopharynx. To ensure adequate washing, the lavage fluid (5 ml of PBS) was passed slowly 
into the nasal cavity via an olive consisting of an oval, hollow, stainless steel device that was 
used to obstruct the nostril. The fluid was withdrawn into the syringe and gently flushed back 
into the nasal cavity 20 times over 1 minute. Samples were centrifuged (4
0
C, 10 minutes at 
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400 g), and the separated supernatant was aliquoted and frozen (−80
0
C). For the 
electrochemiluminescence studies, the levels of IFN‐γ, IL‐4, IL‐5, IL‐10, and IL‐13 in the 
nasal lavage samples were analyzed in duplicates using the Human TH1/TH2 10-plex Ultra-
Sensitive kit from Meso Scale Discovery (MSD, Gaithersburg, MD). Assays were conducted 
according to standard manufacturer’s protocols. MSD plates were analysed on the Sector 
Imager 6000 using MSD Discovery workbench software (v 3.0.17.3). According to 
manufacturer’s protocol, the lower limit of detection for IL-4:0.31 pg/mL, IL5: 0.076 pg/mL, 
IL-13: 1.8 pg/mL, IL10: 0.36 pg/mL, and IFN-γ: 0.39 pg/mL. 
 
Nasal Biopsies, immunohistochemistry staining and quantification 
Nasal biopsies specimens (2.5 mm) were taken from the under surface of the inferior 
turbinate using Gerritsma forceps with lidocaine 5% and phenylephrine 0.5% mixture nasal 
spray and 10% cocaine as local anaesthetic as described previously (E-2). Tissue specimens 
were fixed in 4% paraformaldehyde for 2 hours, then dehydrated in 15% sucrose for 1 h and 
then again overnight, before being embedded in OCT and snap frozen. Five-micron sections 
were cut and slides were dried overnight at 37
0
C and then stored at -80
0
C. 
 
Immunohistochemistry staining and quantification 
Immunohistochemistry was performed using the Vectastatin avidin/biotin complex-alkaline 
phosphatase (ABC-AP) method as described previously (E-2). Briefly, sections were 
incubated with 20% horse serum in PBS for 30 minutes to reduce non-specific binding. 
Mouse monoclonal primary antibodies were applied to slides using pre-determined dilutions 
(E-Table 1) and incubated overnight at 4
o
C. Sections were washed with buffer followed by 
incubation with biotinylated horse anti-mouse secondary antibody and then ABC-AP 
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complex at room temperature (E-Table1). The reaction was developed with Fast Red 
substrate and counterstained with Harris Haematoxylin.  
Biopsy sections were stained using monoclonal antibodies against eosinophils (MBP), mast 
cells (AAI) and basophils (2D7). Upper airway remodeling was assessed by staining vascular 
(CD31) and lymphatic endothelial (D2-40) cells, and vascular endothelial growth factor-A 
(VEGF-A). Furthermore, extracellular matrix activation was evaluated by staining heat shock 
protein-47 (HSP-47, marker of fibroblasts), alpha-smooth muscle actin (α-SMA-those 
expressing myo-fibroblasts) matrix metalloproteinase-7 and 9 (MMP7 & 9) and tissue 
inhibitor of metalloproteinase-1 (TIMP-1). Monoclonal CD3 antibodies and mouse IgG 
isotypes (DakoCytomation, Cambridgeshire, United Kingdom) were used as positive and 
negative controls respectively.  
Reticular basement membrane and epithelial integrity were assessed using haematoxylin 
stained slides. Epithelial goblet cells and the glandular mucus area were evaluated using PAS 
staining. The collagen content was assessed by picrosirius red staining (E-3). Biopsies were 
coded and evaluated blindly by three investigators without the knowledge of clinical 
characteristics.  
Nasal mucosal inflammatory cells, were quantified using a BH-2 Olympus microscope. 
Epithelial integrity was scored on 0-4 scale, with 4 being an intact epithelium. Vascular and 
lymphatic staining was assessed using computer assisted image analysis (Image Pro-Plus 7.0 
system, Media Cybernetics, Inc). The whole specimen was captured at x200 magnification, 
using Nikon 80i light microscope coupled to colour camera (QImaging, Media Cybernetics, 
Inc) that transmits the image to a computer. Images can be magnified up to 200% which 
allows clear identification of stained cells, blood and lymphatic vascular structures. Images 
were captured and examined manually. Epithelial, glandular, total sub-mucosal and vascular 
area was measured separately using computer Image analysis (Image Pro-Plus 7.0 system, 
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Media Cybernetics, Inc). Reticular basement membrane thickness was measured as proposed 
by Sullivan et al (E-4). Epithelial and sub-mucosal cell counts were expressed as the number 
of positively stained nucleated cells per mm
2
.  
The total numbers of CD31
+
 and D2-40
+
cells in the sub-mucosa were counted to a depth of 
200 µm below the epithelium. Blood and lymphatic vessel numbers, the area of each vessel, 
and the total selected area of sub-mucosa were determined by capturing the entire section 
using Image Pro-Plus 7 software. The area of each vessel was measured along the inner 
luminal margin of positively stained endothelial basement membrane and automatically 
calculated using the Image Pro-Plus 7 software. Total vascular area is the sum of the 
individual CD31 or D2-40 vessel areas within a given region (the sub-mucosa to a depth of 
200µm below the basement membrane). The software measurements of the area of positive 
immunostaining in the region of interest were transferred to an Excel spreadsheet for 
statistical analysis and determination of the total number of vessels, vascular area and number 
of positive cells.  
 For each sample the percentage vascular area, the mean vessel size (mm
2
), and the vessel 
number (per mm
2
) within the total area of assessed sub-mucosa was evaluated. Percentage 
vascular area was calculated as [(total vascular area/sub-mucosal area) x 100]; number of 
blood vessels/mm
2
 (vessels density) as (total number of blood vessels/ total sub-mucosal 
area); and mean vessel size/mm
2
 (total vascular area/total number of blood vessels). 
Furthermore, the relative lymphatic vessel density was studied by calculating the ratio of D2-
40/CD31 positive vessels/mm
2
. 
Picrosirius stained collagens were quantified as previously described (E-3). Briefly, colour 
images of two sections from each biopsy were acquired at x200 magnification (with a 
polarizing lens for Picrosirius red–stained sections; Leica QWin version 3). Subsequently, 
images were converted to grayscale, and the area of positive staining that includes reticular 
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basement membrane and whole of sub-mucosa was determined at a preset pixel intensity by 
using the Leica QWin software. The mean area of collagen and total sub-mucosal area was 
used to calculate the percentage area of collagen in each nasal biopsy. 
 
Statistics 
Values are presented as median [IQ 25-75 range], unless otherwise specified. Comparisons 
for quantitative variables were performed by non-parametrical analysis, Mann–Whitney U 
test for non-related samples. Differences between three groups were assessed using Kruskal-
Wallis test (nonnormal distribution) followed by Dunn's multiple comparisons test. Within-
group comparisons were performed by using the Wilcoxon matched-pairs signed-rank test. 
Interobserver reproducibility within 2 standard deviation was measured using Bland-Altman 
test. All tests were two-tailed. Significance was set at P<0.05. GraphPad Prism 5 Project 
software was used for analysis. Further to these tests, we performed limited principal 
component analysis (PCA) using XLSTAT statistical software for Microsoft Excel on the 
data set of allergic rhinitis patients who also had asthma comparing 6 variables (TIMP1, 
MMP-9, Basement membrane thickness, collagen area, total blood and lymphatic vascular 
area) that might be associated with remodeling features. Analysis showed low variability as 
determined by eigenvalue, no correlation between the variables, and no positive contribution 
on allergic rhinitis with asthma as analysed by eigenvectors.  
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Legends: 
Supplement Figure 1: Flow chart of study design. Definition of abbreviations: TNSS= Total 
nasal symptom score, VAS= Visual analogue score, RQoL= Rhinitis quality of life, sIgE= 
Specific IgE. IHC: Immunohistochemistry, SPT: Skin prick test, V1/2: Visit 1 & 2, *: Time 
points. 
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Table 1 Supplement: Primary and secondary antibodies used for Immunohistochemistry 
staining. 
Primary 
antibody 
Clone/Cat.
No 
Source 
Host species- 
Monoclonal 
Working 
Dilution 
Secondary 
antibody 
CD31 M0823 Dako Mouse 1:100 Horse Anti- Mouse 
D2-40 M3619 Dako Mouse 1:150 Horse Anti- Mouse 
VEGF-A sc-7269 
Santa 
Cruz 
Mouse 1:75 Horse Anti- Mouse 
MMP-7 Ab3205 Abcam Mouse 1:20 Horse Anti- Mouse 
MMP-9 Ab51203 Abcam Mouse 1:75 Horse Anti- Mouse 
TIMP-1 
Ab1827-
250 
Abcam Mouse 1:50 Horse Anti- Mouse 
HSP-47 SPA470 Stressgen Mouse 1:800 Horse Anti- Mouse 
α-SMA M0851 DAKO Mouse 1:800 Horse Anti- Mouse 
AA1 M7052 DAKO Mouse 1:50 Horse Anti- Mouse 
MBP MCA5751 Bio-RAD Mouse 1:50 Horse Anti- Mouse 
2D7 B136194 Biolegend Mouse 1:50 Horse Anti- Mouse 
Definition of abbreviations: CD31: Vascular endothelial cells, D2-40: Lymphatic endothelial 
cells, VEGF-A: Vascular endothelial growth factor, MMP: Matrix metalloproteinase, α-
SMA= Alpha smooth muscle actin, TIMP= Tissue inhibitor metalloproteinase, HSP= Heat 
shock protein, MBP: Major basic protein, 2D7: Basophils marker, AA1: Mast cells marker 
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Table 2 Supplement: Demographic features of participants 
 Seasonal AR 
n=23 
Perennial AR 
n= 23 
Controls 
n=19 
p value 
Age yrs 
28 (23-34) 31 (27-41) 30 (26-45) 0.29 
Gender F/M 
11/12 13/10 11/8 0.77 
TNSS 
9 (7-11)  4 (3-6)  0 (0-1) <0.0001 
TVAS 
(24 13-45)  64 (44-71)  1 (0-7) <0.0001 
Total RQoL 
3 (2-3.6)  1 (1-2)  0 (0-0.2) <0.0001 
Eczema % 
30(n:7) 13(n:3) -(n:0) <0.0001 
Asthma % 
30 (n:7) 26 (n:6) -(n:0) <0.0001 
sIgE Grass IU/mL 
15 (5-34)  9 (1-61)  0 (0) <0.0001 
sIgE HDM IU/mL 
1 (0-2.5)  16 (12-48) 0 (0) <0.0001 
Total IgE IU/mL 
74 (28-195)  244 (117-687) 15 (4-49) <0.0001 
Definition of abbreviations: TNSS= Total nasal symptoms score, TVAS= Total visual 
analogue score, RQoL= Rhinitis quality of life, sIgE= Specific IgE. 
Median (IQR:25-75 %)  
***
: p<0.0001, Kruskall wallis test comparing seasonal and perennial rhinitis with control. 
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Table 3 Supplement: Summary of airway remodeling markers in upper airways in 
severe persistent allergic rhinitis and healthy controls. 
 Natural exposure (severe PAR) 
 
Normals Perennial AR In Season AR 
Out-season 
AR** 
p* 
Epithelial Mucus % 
Area 
10 (3-22) 17 (6-38) 18 (2-33) 4 (1-18) 0.54 
RBM Thickness 9 (7-10) 8 (7-11) 8 (6-9) 8 (6-10) 0.60 
Submucosal Glandular 
% Area/ mm2 
34(21-43) 32 (17-50) 31 (11-45) 20 (11-35) 0.99 
CD31
+
 Cells /mm
2
 333 (180-566) 367 (193-480) 370 (217-470) 308 (214-480) 0.91 
CD31
+
 % Vascular area/ 
mm
2
 
1.7 (1.1-3.9) 1.5 (0.4-3.8) 1.7 (0.4-3.4) 1.7 (1.7-3.1) 0.68 
Number of Blood 
vessels/mm
2
 
41.3(18-58) 34.3(28-49) 40(30-56) 41(30-61) 0.59 
Mean size blood 
vessels/µm
2
 
532(270-1010) 306(112-1022) 406(171-673) 479(276-691) 0.30 
D2-40
+
 Cells/ mm
2
 0 (0-51) 0 (0-28) 0 (0-85) 0 (0-22) 0.31 
D2-40
+
 % Vascular 
area/ mm
2
 
0 (0-0.2) 0 (0-0.4) 0 (0-0.6) 0 (0-0.1) 0.62 
Number of Lymphatic 
vessels/mm
2
 
0 (0-6) 0 (0-3.5) 0 (0-11) 0 (0-5.8) 0.32 
Mean size Lymphatic 
vessels/µm
2
 
0 (0-494) 0 (0-873) 0 (0-426) 0 (0-260) 0.86 
D2-40
+
/CD31
+
 
vessels/mm
2
 ratio 
0 (0-0.19) 0 (0-0.07) 0 (0-0.15) 0 (0-0.1) 0.59 
D2-40
+
/CD31
+
 % 
area/mm
2
 ratio 
0 (0-0.1) 0 (0-0.14) 0 (0-0.2) 0 (0-0.1) 0.76 
VEGF-A
+
 cells/ mm
2
 80 (0-129) 67.4 (0-116) 30.7 (0-121) 107 (0-179) 0.73 
VEGF-A
+
 % vascular 
Area/ mm
2
 
0.2 (0-0.7) 0.5 (0-1.5) 0.2 (0-0.8) 0.4 (0-1.5) 0.24 
MMP-7
+
 cells/ mm
2
 1 (0-60) 0 (0-6) 0 (0-12) 0 (0-30) 0.40 
MMP-9
+
 cells/ mm
2
 6.7 (0-27.7) 10 (3-30) 6.2 (0-16) 12 (3-49) 0.32 
TIMP-1
+
 cells/ mm
2
 0 (0-3) 0 (0-10) 0 (0-1.6) 2 (0.8-8) 
§ 0.61 
HSP-47
+
 Fibroblast/mm
2
 0 (0-15) 0 (0-0.8) 0 0 (0-20) 0.11 
α-SMA/ mm
2
 130 (62-217) 124 (53-240) 92 (51-165) 81 (17-170) 0.49 
Definition of abbreviations: α-SMA= Alpha-smooth muscle actin, TIMP= Tissue inhibitors of 
metalloproteinase, MMP= Matrix metalloproteinase, HSP= Heat shock protein, VEGF= Vascular endothelial 
growth factor, CD31= Vascular endothelial cells, D2-40= Lymphatic endothelial cells, RBM= Reticular 
basement membrane, AR= Allergic Rhinitis. Median (25%-75%). 
*Kruskall wallis test: comparing in or out of season, perennial and healthy controls.  
**Wilcoxon signed rank test: comparing between in season and out of season.  
§
 p<0.01, Significant statistical difference between in season and out of season.. 
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E-Fig 1 Supplement. Flow chart of study design 
V1: 
Screening 
Serum: TIgE, sIgE 
SPT 
46 Persistent AR 
 *
  
Inclusion/Exclusion 
Nasal secretion: Cytokines 
      IL-4, 5, 13, 10, IFN-γ 
Nasal Biopsy: Immunohistochemistry 
Epithelial and Inflammatory cells, 
reticular basement membrane, glandular 
area, vascularity, collagen markers 
19 Healthy control 
V2: Persistent  (Seasonal & Perennial AR) 
TNSS/VAS/RQoL 
 *
  
 *
  
 *
  
 *
  
 *
  
Subjects recruited: n=65 
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